Moneira A Mansour^1,2*

¹Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taibah University, Al-Madinah Al Munawarah, KSA

*Corresponding Author: Moneira A Mansour, Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taibah University, Al-Madinah Al Munawarah, KSA and College of Medical Laboratory Science, Sudan University of Science and Technology, Khartoum, Sudan.

Received: December 05, 2022; Published: January 11, 2023

Abstract

Cervical cancer is abnormal growth of cells in the uterine cervix generally at the district of the uterus that joins the vagina. It can be spread to other organs in the human body if untreated. Previously it ranked the second cancer affecting ladies worldwide after breast cancer and second causing cancer death among women. Recently, it is the fourth-most common cancer worldwide and the fourth-most common cause of cancer death in women. The most common type of cervical cancer is squamous cell carcinoma followed by adenocarcinoma, while other type is less in number. This paper focusing on a major type; squamous cell carcinoma.

Keywords: Cervical Cancer; Cervical Intra Epithelial Neoplasia (CIN); Risk Factors; Prevention; Etiology; Treatment

References

1. Ferlay J., et al. “Global Cancer Observatory: Cancer Today”. Lyon, France: International Agency for Research on Cancer (2018).
2. Sung H., et al. “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: A Cancer Journal for Clinicians 71 (2021): 209-249.
3. American Cancer Society. Cancer Facts and Figures 2021. Atlanta, GA: American Cancer Society (2021).
4. Atun R., et al. “Expanding global access to radiotherapy”. Lancet Oncology10 (2015): 1153-1186.
5. Brisson M., et al. “Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries”. Lancet 10224 (2020): 575-590.
6. Kumar V., et al. “Robbins Basic Pathology (8^th)”. Saunders Elsevier (2007): 718-721.
7. Nanda R. "Cervical Cancer". MedlinePlus Medical Encyclopedia. National Institutes of Health.
8. McMurray HR., et al. “Biology of human papillomaviruses”. International Journal of Experimental Pathology 1 (2006): 15-33.
9. Walboomers JM., et al. “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. Journal of Pathology 189 (1999): 12-19.
10. De Sanjosé S., et al. “Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis”. Lancet Infectious Diseases 7 (2007): 453-459.
11. Burd EM. “Human papillomavirus and cervical cancer”. Clinical Microbiology Reviews1 (2003): 1-17.
12. Xi LF., et al. “Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load”. Cancer Epidemiology, Biomarkers and Prevention 12 (2009): 3490-3496.
13. Moscicki AB., et al. “Chapter 5: Updating the natural history of HPV and anogenital cancer”. Vaccine 24 (2006): S3/42-51.
14. Kumar V., et al. “Robbins Basic Pathology 9^th ed”. Philadelphia, PA: Elsevier/Saunders (2013): 668-669.
15. Nagelhout G., et al. “Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis”. Expert Review of Anticancer Therapy 7 (2021): 781-794.
16. Sanjay S P., et al. “AMRITA CEN-NLP@ FIRE 2015: CRF Based Named Entity Extractor For Twitter Microposts”. In FIRE Workshops (pp. 96-99). Greenwald, P. (2002). Cancer chemoprevention. Bmj 324.7339 (2015): 714-718.
17. Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, Colton T, Hartge P, Hatch EE, Herbst AL, Karlan BY, Kaufman R, Noller KL, Palmer JR, Robboy SJ, Saal RC, Strohsnitter W, Titus-Ernstoff L, Troisi R. (2011).
18. Ganguly N and Parihar SP. "Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis". Journal of Biosciences1 (2009): 113-123.
19. Fradet-Turcotte A and Archambault J. “Recent advances in the search for antiviral agents against human papillomaviruses”. Antivirus Therapy4 (2007): 431-451.
20. Hebner CM and Laimins LA. “Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity”. Reviews in Medical Virology 2 (2006): 83-97.
21. Arbyn M., et al. “Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis”. Lancet Global Health2 (202): e191-e203.
22. Dijkstra MG., et al. “Cervical cancer screening: on the way to a shift from cytology to full molecular screening”. Annals of Oncology (2014).
23. Bruni L., et al. “Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis”. Lancet Global Health 4 (2016): e453-e463.
24. “Human papillomavirus vaccines: WHO position paper”. Biologicals 37 (2009): 338-344.
25. World Health Organization. Regional Office for South-East Asia. Strategic framework for the comprehensive control of cancer cervix in South-East Asia Region. New Delhi WHO (2015).
26. Markowitz LE., et al. “Human papillomavirus vaccine introduction-the first five years”. Vaccine 30 (2012): F139-148.
27. Brotherton JM., et al. “Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study”. Lancet 377 (2011): 2085-2092.
28. Agorastos T., et al. “Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far”. Vaccine 27 (2009): 7270-7281.
29. Lu B., et al. “Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis”. BMC Infectious Diseases 11 (2011): 13.
30. Manhart LE and Koutsky LA. "Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis". Sexually Transmitted Diseases 11 (2002): 725-735.
31. American Cancer Society. Cancer Facts and Figures 2020, Inc. No. 500820-Rev 6/20 (2020).
32. Sedjo RL., et al. “Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection". Cancer Epidemiology, Biomarkers and Prevention 9 (2002): 876-884.
33. Zhang X., et al. “Vitamin A and risk of cervical cancer: A meta-analysis”. Gynecologic Oncology 2 (2012): 366-373.
34. Myung SK., et al. “Korean Meta-analysis (KORMA) Study Group. Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a meta-analysis”. BJOG 11 (2011): 1285-1291.
35. Kumar H., et al. “Line Immunoassay: A Rapid Test for Screening TORCH Complex in Antenatal Patients with Bad Obstetric History”. Mymensingh Medical Journal: MMJ3 (2018): 641-644.
36. Siegel RL., et al. “Cancer statistics, 2020”. CA: A Cancer Journal for Clinicians 1 (2020): 7-30.
37. Massad LS., et al. “2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors”. Journal of Lower Genital Tract Disease 5 (2011): S1-S27.
38. Ronco G., et al. “Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials”. Lancet 383 (2014): 524-532.
39. Vassilakos P., et al. “Cervical cancer screening in Switzerland: time to rethink the guidelines”. Swiss Medical Weekly 145 (2015): w14112.
40. Sauvaget C., et al. “Accuracy of visual inspection with acetic acid for cervical cancer screening”. International Journal of Gynecology and Obstetrics 113 (2011): 14-24.
41. Shastri SS., et al. “Effect of via screening by primary health workers: randomized controlled study in Mumbai”. Journal of the National Cancer Institute 103 (2014): dju009.
42. Sankaranarayanan R., et al. “Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa”. Vaccine 31 (2013): F47-F52.
43. Wright TC., et al. “Alternative approaches to cervical cancer screening for developing countries”. Best Practice and Research Clinical Obstetrics and Gynaecology 26 (2012): 197-208.
44. Jeronimo J., et al. “A multicountry evaluation of care HPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer”. International Journal of Gynecological Cancer 24 (2014): 576-585.
45. World Health Organization. WHO guidance note: comprehensive cervical cancer prevention and control: A healthier future for girls and women. Geneva: World Health Organization (2013).
46. Turkot M., et al. “External audit of providers of the Cervical Cancer Prevention Programme in Poland in 2016/2017”. Nowotwory Journal of Oncology 68 (2018): 65-78.
47. Sherris Jacqueline., et al. “Evidence-Based, Alternative Cervical Cancer Screening Approaches in Low-Resource Settings”. International Perspectives on Sexual and Reproductive Health3 (2009): 147-152.
48. Pannu HK., et al. “CT evaluation of cervical cancer: spectrum of disease”. Radio Graphics 21 (2001): 1155-1168.
49. Bhatla N., et al. “Revised FIGO staging for carcinoma of the cervix uteri”. International Journal of Gynecology and Obstetrics 145 (2019): 129-135.
50. National Guidelines: CIN, AIS and VAIN version 1.0 (in Dutch). Nijmegen: Integraal Kankercentrum Nederland (2015).

Citation

Citation: Moneira A Mansour. “Review on Uterine Cervix Cancer". Acta Scientific Microbiology 6.2 (2023): 37-44.

Copyright

Copyright: © 2022 Moneira A Mansour. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.